Interactions between the sympathetic nervous system and the RAAS in heart failure

Current Heart Failure Reports

Volumn 1, Issue 2, 2004, Pages 45-50

  Goldsmith, Steven R ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Carvedilol; Chronic Heart Failure; Enalapril; Eplerenone; Heart Failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADRENERGIC SYSTEM; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 26044439114     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-004-0024-5     Document Type: Article

References (34)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429–1435. DOI: 10.1056/NEJM198706043162301
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302. DOI: 10.1056/NEJM199108013250501
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007.
5. Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. DOI: 10.1056/NEJMoa010713
6. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. DOI: 10.1056/NEJM199909023411001
7. Packer M, Bristow M, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355. DOI: 10.1056/NEJM199605233342101
8. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658. DOI: 10.1056/NEJM200105313442201
9. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003, 362:759–766. DOI: 10.1016/S0140-6736(03)14282-1
10. Goldsmith SR: Therapeutics in congestive heart failure: from hemodynamics to neurohormones. In Cardiac Remodeling and Failure. Edited by Singal P, Dixon I, Kirshenbaum LA, Dhalla N. Boston: Kluwer Academic Publishers; 2003:17–34. This is a thorough review of the past 20 years of pharmacologic treatment for heart failure, with an emphasis on how neurohormonally based therapy has supplanted therapy directed at hemodynamics. It also includes a discussion of the mechanisms of sympathoactivation in heart failure.
11. Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996, 94:2285–2296.
12. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022–1036.
13. Engelmeier RS, O’Connell JB, Walsh R, et al.: Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985, 72:536–546.
14. Cody RJ, Laragh JH: The renin-angiotensin-aldosterone system in chronic heart failure. In Drug Treatment of Heart Failure. Secaucus, NY: ATC; 1988:81. This is a thorough review of the role of the RAAS in heart failure, with therapeutic and mechanistic implications.
15. Jorde UP, Ennezat PV, Lisker J, et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000, 101:844–846.
16. Francis GS, Siegel RM, Goldsmith SR, et al.: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985, 103:1–6.
17. Campbell DJ, Aggarwal A, Esler M, Kaye D: Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001, 358:1609–1610. This is a good discussion of the interaction of the various neurohormonal systems in clinical heart failure. DOI: 10.1016/S0140-6736(01)06660-0
18. Cohn JN: Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure. J Renin Angiotensin Aldosterone Syst 2003, 4:137–139. DOI: 10.3317/jraas.2003.021
19. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. DOI: 10.1056/NEJMoa030207
20. Zucker IH, Wang W, Brandle M, et al.: Neural regulation of sympathetic nerve activity in heart failure. Prog Cardiovasc Dis 1995, 37:397–414. DOI: 10.1016/S0033-0620(05)80020-9
21. Goldsmith SR: Angiotensin II and sympathoactivation in heart failure. J Card Fail 1999, 5:139–145. This is a thorough review of the effects of angiotensin II on sympathetic activity, with an emphasis on clinical relevance to heart failure. DOI: 10.1016/S1071-9164(99)90036-2
22. Wang W, Zucker IH: Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Am J Physiol 1996, 271:R751-R756.
23. Ma R, Zucker IH, Wang W: Reduced NO enhances the central gain of cardiac sympathetic afferent reflex in dogs with heart failure. Am J Physiol 1999, 276:H19-H26.
24. Clemson B, Gaul L, Gubin SS, et al.: Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994, 93:684–691.
25. Goldsmith SR, Hasking GJ: Subpressor infusions of angiotensin II do not stimulate sympathetic activity in humans. Am J Physiol 1990, 258:H179-H182.
26. Goldsmith SR, Hasking GJ: Angiotensin II and sympathetic nervous activity in patients with congestive heart failure. J Am Coll Cardiol 1993, 21:1107–1113. DOI: 10.1016/0735-1097(93)90232-P
27. Goldsmith SR, Rector TS, Bank AJ, et al.: Effect of angiotensin II on noradrenaline release in the human forearm. Cardiovasc Res 1994, 28:663–666. DOI: 10.1093/cvr/28.5.663
28. Goldsmith SR, Garr M, McLaurin M: Regulation of regional norepinephrine spillover in heart failure: the effect of angiotensin II and beta-adrenergic agonists in the forearm circulation. J Card Fail 1998, 4:305–310. DOI: 10.1016/S1071-9164(98)90236-6
29. Goldsmith SR, Hasking GJ: Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans. Circ Res 1991, 68:263–268.
30. Murakami H, Liu JL, Zucker IH: Angiotensin II enhances (ibid.) baroreflex control of sympathetic outflow in heart failure. Hypertension 1997, 29:564–569.
31. Kasama S, Toyama T, Kumakura H, et al.: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003, 41:574–581. DOI: 10.1016/S0735-1097(02)02855-3
32. Grassi G, Cattaneo BM, Seravalle G, et al.: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997, 96:1173–1179. This is perhaps the key paper linking therapy with ACEI to diminished activity of the sympathetic nervous system in heart failure.
33. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310. DOI: 10.1056/NEJM199108013250502
34. Francis GS, Cohn JN, Johnson G, et al.: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:VI40-VI48. This is a provocative analysis linking differential outcomes of therapies in the V-HEFT II trial to the effects of those therapies on plasma norepinephrine levels.